Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis

Critical Reviews in Clinical Laboratory Sciences

Volumn 42, Issue 1, 2005, Pages 71-104

  Tuckermann, Jan P ^a   Kleiman, Anna ^a   McPherson, Kirsty G ^b   Reichardt, Holger M ^b  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Apoptosis; Dendritic cells; Glucocorticoids; Immimosuppressants; Inflammation; Thymocytes; Transcription

Indexed keywords

ALPHA FETOPROTEIN; ANTIINFLAMMATORY AGENT; CASPASE; CERAMIDE; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; HYDROGEN PEROXIDE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; OSTEOCALCIN; PROLACTIN; PROOPIOMELANOCORTIN; PROTEASOME; PROTEIN BCL 2; GLUCOCORTICOID RECEPTOR;

APOPTOSIS; AUTOIMMUNITY; BONE MARROW CELL; CANCER; CELL INTERACTION; DENDRITIC CELL; GRANULOCYTE; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY DISEASE; MACROPHAGE; MAST CELL; PRIORITY JOURNAL; REVIEW; STROMA CELL; T LYMPHOCYTE; THYMOCYTE; ANIMAL; DRUG EFFECT; GENETICS; HUMAN; LYMPHOCYTE; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LYMPHOCYTES; RECEPTORS, GLUCOCORTICOID;

EID: 18244397482     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360590888983     Document Type: Review

References (187)

1. Hench PS, Kendall EC, Slocumb CH, Policy HF. Effects of cortisone acetate and pituitray ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Int Med 1950; 85: 545-66.
2. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999; 402: B31-8.
3. Kofler R, Schmidt S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003; 178: 19-27.
4. Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: Summary of a workshop. J Clin Endocrinol Metab 2001; 86: 5681-5.
5. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227-32.
6. Peeke PM, Chrousos GP. Hypercortisolism and obesity. Ann NY Acad Sci 1995; 771: 665-76.
7. Reichardt HM, Tronche F, Bauer A, Schütz G. Molecular genetic analysis of glucocorticoid signaling using the Cre/1oxP system. Biol Chem 2000; 381: 961-4.
8. Miesfeld R, Okret S, Wikstrom AC, Wrange O, Gustafsson JA, Yamamoto KR. Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells. Nature 1984; 312: 779-81.
9. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835-9.
10. Beato M, Herrlich P, Schütz G. Steroid hormone receptors: Many actors in search of a plot. Cell 1995; 83: 851-7.
11. Pratt WB, Gehring U, Toft DO. Molecular chaperoning of steroid hormone receptors. EXS 1996; 77: 79-95.
12. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002; 296: 2232-5.
13. Stavreva DA, Muller WG, Hager GL, Smith CL, McNally JG. Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. Mol Cell Biol 2004; 24: 2682-97.
14. Freedman ND, Yamamoto KR. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol Biol Cell 2004; 15: 2276-86.
15. Kino T, Souvatzoglou E, De Martino MU, Tsopanomihalu M, Wan Y, Chrousos GP. Protein 14-3-3sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J Biol Chem 2003; 278: 25651-6.
16. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002; 110: 93-105.
17. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 1991; 352: 497-505.
18. McNally JG, Muller WG, Walker D, Wolford R, Hager GL. The glucocorticoid receptor: Rapid exchange with regulatory sites in living cells. Science 2000; 287: 1262-5.
19. Becker M, Baumann C, John S, Walker DA, Vigneron M, McNally JG, Hager GL. Dynamic behavior of transcription factors on a natural promoter in living cells. EMBO Rep 2002; 3: 1188-94.
20. Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR. Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 1992; 258: 1598-604.
21. Cairns BR, Levinson RS, Yamamoto KR, Kornberg RD. Essential role of Swp73p in the function of yeast Swi/Snf complex. Genes Dev 1996; 10: 2131-44.
22. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR. Regulation of transcription by a protein methyltransferase. Science 1999; 284: 2174-7.
23. Ma H, Baumann CT, Li H, Strahl BD, Rice R, Jelinek MA, Aswad DW, Allis CD, Hager GL, Stallcup MR. Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Cell Biol 2001; 11: 1981-5.
24. Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999; 97: 5-8.
25. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001; 20: 7108-16.
26. Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J Biol Chem 2003; 278: 18022-9.
27. Deroo BJ, Archer TK. Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol Biol Cell 2001; 12: 3365-74.
28. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A, Cannarile L, Migliorati G, Riccardi C. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803-12.
29. Nocentini G, Giunchi L, Ronchetti S, Krausz LT, Bartoli A, Moraca R, Migliorati G, Riccardi C. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 6216-21.
30. Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, Darimont BD, Garabedian MJ, Yamamoto KR. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl Acad Sci USA 2003; 100: 13845-50.
31. Schmid E, Schmid W, Jantzen M, Mayer D, Jastorff B, Schutz G. Transcription activation of the tyrosine aminotransferase gene by glucocorticoids and cAMP in primary hepatocytes. Eur J Biochem 1987; 165: 499-506.
32. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997; 66: 581-611.
33. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, Cato AC. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 1994; 13: 4087-95.
34. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J 1997; 16: 4698-707.
35. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-41.
36. Reichardt HM, Tuckermann JP, Göttlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schütz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001; 20: 7168-73.
37. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependentgenes in skin. J Cell Biol 1999; 147: 1365-70.
38. Tronche F, Opherk C, Moriggl R, Kellendonk C, Reimann A, Schwake L, Reichardt HM, Stangl K, Gau D, Hoeflich A, Beug H, Schmid W, Schutz G. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev 2004; 18: 492-7.
39. Tronche F, Kellendonk C, Reichardt HM, Schutz G. Genetic dissection of glucocorticoid receptor function in mice. Curr Opin Genet Dev 1998; 8: 532-8.
40. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85: 403-14.
41. De Bosselier K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the ce11. Proc Natl Acad Sci USA 2000; 97: 3919-24.
42. De Bosscher K, Vanden Berghe W, Haegeman G. Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Mol Endocrinol 2001; 15: 219-27.
43. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappaB synthesis. Science 1995; 270: 286-90.
44. Scheinman RI, Cogswell PC, ofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of Immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
45. Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ.J Biol Chem 2001; 276:29603-10.
46. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid-mediated repression of nuclear factor-kappaB- dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 1997; 94: 13504-9.
47. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000; 14: 2314-29.
48. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997; 11: 1245-55.
49. Zhang G, Zhang L, Duff GW. A negative regulatory region containing a glucocorticosteroid response element (nGRE) in the human interleukin-lbeta gene. DNA Cell Biol 1997; 16: 145-52.
50. Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M, Schmidt TJ. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J 1993; 12: 145-56.
51. Stromstedt PE, Poellinger L, Gustafsson JA, Carlstedt-Duke J. The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: A potential mechanism for negative regulation. Mol Cell Biol 1991; 11: 3379-83.
52. Poliard A, Bakkali L, Poiret M, Foiret D, Danan JL. Regulation of the rat alpha-fetoprotein gene expression in liver. Both the promoter region and an enhancer element are liver-specific and negatively modulated by dexamethasone. J Biol Chem 1990; 265: 2137-41.
53. Sakai DD, Helms S, Carlstedt Duke J, Gustafsson JA, Rottman FM, Yamamoto KR. Hormonemediated repression: A negative glucocorticoid response element from the bovine prolactin gene. Genes Dev 1988; 2: 1144-54.
54. Malkoski SP, Handanos CM, Dorin RI. Localization of a negative glucocorticoid response element of the human corticotropin releasing hormone gene. Mol Cell Endocrinol 1997; 127: 189-99.
55. Limbourg FP, Huang Z, Plumier JC, Simoncini T, Fujioka M, Tuckermann J, Schutz G, Moskowitz MA, Liao JK. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002; 110: 1729-38.
56. Limbourg FP, Liao JK. Nontranscriptional actions of the glucocorticoid receptor. J Mol Med 2003; 81:68-74.
57. Bruna A, Nicolas M, Munoz A, Kyriakis JM, Caelics C. Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J 2003; 22: 6035-44.
58. Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science 1993; 259: 1132-3.
59. Armanini D, Spinella P, Simoncini M, Basso A, Zovato S, Pozzan GB, De Palo CB, Bucciante G, Karbowiak I. Regulation of corticosteroid receptors in patients with anorexia nervosa and Cushing's syndrome. J Endocrinol 1998; 158: 435-9.
60. Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M, Radbruch A, Burmester GR, Lauster R, Scheffold A, Buttgereit F. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004; 18: 70-80.
61. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002; 67: 529-34.
62. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
63. + regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-47.
64. Vremec D, Shortman K. Dendritic cell subtypes in mouse lymphoid organs: Cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 1997; 159: 565-73.
65. Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 2000; 165: 4910-6.
66. + T cell tolerance. Immunity 2003; 18: 713-20.
67. Shortman K, Heath WR. Immunity or tolerance? That is the question for dendritic cells. Nat Immunol 2001; 2: 988-9.
68. Randolph GJ. Is maturation required for Langerhans cell migration? J Exp Med 2002; 196: 413-6.
69. Moser M, De Smedt T, Sornasse T, Tielemans F, Chentoufi AA, Muraille E, Van Mechelen M, Urbain J, Leo O. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur J Immunol 1995; 25: 2818-24.
70. Shodell M, Siegal FP. Corticosteroids depress IFN-alpha-producing plasmacytoid dendritic cells in human blood. J Allergy Clin Immunol 2001; 108: 446-8.
71. Grabbe S, Steinbrink K, Steinert M, Luger TA, Schwarz T. Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. J Immunol 1995; 155: 4207-17.
72. Holt PG, Thomas JA. Steroids inhibit uptake and/or processing but not presentation of antigen by airway dendritic cells. Immunology 1997; 91: 145-50.
73. Piemonti L, Monti P, Allavena P, Leone BE, Caputo A, Di Carlo V. Glucocorticoids increase the endocytic activity of human dendritic cells. Int Immunol 1999; 11: 1519-26.
74. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, Socci C, Di Carlo V. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999; 162: 6473-81.
75. Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of Corticosteroids during different stages of dendritic cell maturation. Eur J Immunol 2000; 30: 1233-42.
76. Cumberbatch M, Dearman RJ, Kimber I. Inhibition by dexamethasone of Langerhans cell migration: Influence of epidermal cytokine signals. Immuno pharmacology 1999; 41: 235-43.
77. + lymphocytes. J Immunol 1997; 158: 5589-95.
78. + T cells in vitro. J Immunol 1996; 156: 2406-12.
79. Jabara HH, Brodeur SR, Geha RS. Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. J Clin Invest 2001; 107: 371-8.
80. Wu CY, Sarfati M, Heusser C, Fournier S, Rubio-Trujillo M, Peleman R, Delespesse G. Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes. J Clin Invest 1991; 17: 870-7.
81. Barnes PJ. Corticosteroids, IgE, and atopy. J Clin Invest 2001; 107: 265-6.
82. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156: 4422-8.
83. Heasman SJ, Giles KM, Ward C, Rossi AG, Haslett C, Dransfield I. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: Implications for the resolution of inflammation. J Endocrinol 2003; 178: 29-36.
84. Frossi B, De Carli M, Pucillo C. The mast cell: An antenna of the microenvironment that directs the immune response. J Leukoc Biol 2004.
85. Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy 2000; 55 S62: 6-11.
86. Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britten K, Bews JP, Hunt TC, Okayama Y, Heusser CH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 176: 1381-6.
87. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med l995; 181: 1373-80.
88. Krishnaswamy G, Lakshman T, Miller AR, Srikanth S, Hall K, Huang SK, Suttles J, Smith JK, Stout R. Multifunctional cytokine expression by human mast cells: Regulation by T cell membrane contact and glucocorticoids. J Interferon Cytokine Res 1997; 17: 167-76.
89. Lavker RM, Schechter NM. Cutaneous mast cell depletion results from topical corticosteroid usage. J Immunol 1985; 135: 2368-73.
90. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: In vitro and in vivo evidence in murine systems. J Clin Invest 1997; 99: 1721-8.
91. Yoshikawa H, Nakajima Y, Tasaka K. Glucocorticoid suppresses autocrine survival of mast cells by inhibiting IL-4 production and ICAM-I expression. J Immunol 1999; 162: 6162-70.
92. Sakai H, Toyota N, Ito F, Takahashi H, Hashimoto Y, Iizuka H. Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression. Arch Dermatol Res 1999; 291: 224-31.
93. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann NY Acad Sci 2002; 966: 108-18.
94. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the anti-inflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992; 89: 9991-5.
95. Pitzalis C, Pipitone N, Bajocchi G, Hall M, Goulding N, Lee A, Kingsley G, Lanchbury J, Panayi G. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: An additional mechanism for their anti-inflammatory and immunosuppressive effect. J Immunol 1997; 158: 5007-16.
96. Cunha FQ, Ferreira SH. The release of a neutrophil chemotactic factor from peritoneal macrophages by endotoxin: Inhibition by glucocorticoids. Eur J Pharmacol 1986; 129: 65-76.
97. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917-21.
98. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-9.
99. Werb Z. Biochemical actions of glucocorticoids on macrophages in culture. Specific inhibition of elastase, collagenase, and plasminogen activator secretion and effects on other metabolic functions. J Exp Med 1978; 147: 1695-712.
100. Norton JM, Munck A. In vitro actions of glucocorticoids on murine macrophages: Effects on glucose transport and metabolism, growth in culture, and protein synthesis. J Immunol 1980; 125: 259-66.
101. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma Interferon. J Clin Invest 1985; 76: 1755-64.
102. Schaffner A, Schaffner T. Glucocorticoid-induced impairment of macrophage antimicrobial activity: Mechanisms and dependence on the state of activation. Rev Infect Dis 1987; 9S5: S620-9.
103. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996; 60: 563-72.
104. Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: Control of TNF-alpha secretion. Inflamm Res 1997; 46: 447-51.
105. Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B. Mol Pharmacol 1996; 49: 15-21.
106. Berrebi D, Bruscoli S, Cohen N, Poussat A, Migliorati G, Bouchet-Delbos L, Maillot MC, Portier A, CoudercJ, Galanaud P, Peuchmaur M, Riccardi C, Emilie D. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: An anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-1O.Blood 2003; 101: 729-38.
107. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002; 30(1S): S27-S35.
108. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274: 18100-6.
109. Thorn CF, Lu ZY, Whitehead AS. Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAAl and SAA2, by glucocorticoids in hepatic and epithelial cells. Eur J Immunol 2003; 33: 2630-9.
110. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 1999; 23: 99-103.
111. Brewer JA, Khor B, Vogt SK, Muglia LM, Fujiwara H, Haegele KE, Sleckman BP, Muglia LJ. T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat Med 2003; 9: 1318-22. Epub 2003 Aug. 31.
112. Campos RA, Szczepanik M, Itakura A, Akahira-Azuma M, Sidobre S, Kronenberg M, Askenase PW. Cutaneous immunization rapidly activates liver invariant Valpha l4 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J Exp Med 2003; 198: 1785-96.
113. Tsuji RF, Szczepanik M, Kawikova I, Paliwal V, Campos RA, Itakura A, Akahira-Azuma M, Baumgarth N, Herzenberg LA, Askenase PW. B cell-dependent T cell responses: IgM antibodies are required to elicit contact sensitivity. J Exp Med 2002; 196: 1277-90.
114. Tsuji RF, Kawikova I, Ramabhadran R, Akahira-Azuma M, Taub D, Hugli TE, Gerard C, Askenase PW. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol 2000; 165: 1588-98.
115. McHale JF, Harari OA, Marshall D, Haskard DO. Vascular endothelial cell expression of ICAM-1 and VCAM-1 at the onset of eliciting contact hypersensitivity in mice: Evidence for a dominant role of TNF-alpha. J Immunol 1999; 162: 1648-55.
116. Hwang JM, Yamanouchi J, Santamaria P, Kubes P. A critical temporal window for selectin-dependent CD4+ lymphocyte homing and initiation of late-phase inflammation in contact sensitivity. J Exp Med 2004; 199: 1223-34.
117. Budd RC. Activation-induced cell death. Curr Opin Immunol 2001; 13: 356-62.
118. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Not Immunol 2003; 4: 410-5.
119. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-33.
120. Grillot DA, Merino R, Nunez G. Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 1995; 182: 1973-83.
121. Gratiot-Deans J, Ding L, Turka LA, Nunez G. Bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation. J Immunol 1993; 151: 83-91.
122. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol 2003; 21: 71-105.
123. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing LAP proteins. Cell 2000; 102:43-53.
124. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185-93.
125. Yin XM. Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-Rl death receptors in hepatocytes. J Mol Med 2000; 78: 203-11.
126. Jäättelä M, Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol 2003; 4: 416-23.
127. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schütz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995; 9: 1608-21.
128. Cole TJ, Myles K, PurtonJF, Brereton PS, Solomon NM, Godfrey DI, Funder JW. GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol Cell Endocrinol 2001; 173: 193-202.
129. Mittelstadt PR, Ashwell JD. Disruption of glucocorticoid receptor exon 2 yields a ligand-responsive C-terminal fragment that regulates gene expression. Mol Endocrinol 2003; 17: 1534-42.
130. Purton JF, Boyd RL, Cole TJ, Godfrey DI. Intrathymic T cell development and selection proceeds normally in the absence of glucocorticoid receptor signaling. Immunity 2000; 13: 179-86.
131. Purton JF, Zhan Y, Liddicoat DR, Hardy CL, Lew AM, Cole TJ, Godfrey DI. Glucocorticoid receptor deficient thymic and peripheral T cells develop normally in adult mice. Eur J Immunol 2002; 32: 3546-55.
132. Brewer JA, Kanagawa O, Sleckman BP, Muglia LJ. Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J Immunol 2002; 169: 1837-43.
133. Pazirandeh A, XueY, Prestegaard T,Jondal M, OkretS. Effects of altered glucocorticoid sensitivity in the T cell lineage on thymocyte and T cell homeostasis. FASEB J 2002; 16: 727-9.
134. Reichardt HM, Umland T, Bauer A, Kretz O, Schütz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol Cell Biol 2000; 20:9009-17.
135. Reichardt HM, Schütz G. Glucocorticoid signalling-multiple variations of a common theme. Mol Cell Endocrinol 1998; 146: 1-6.
136. Barnes PJ. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998; 94: 557-72.
137. Göttlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor. J Mol Med 1998; 76: 480-9.
138. Helmberg A, Auphan N, Gaelics C, Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 1995; 14: 452-60.
139. Forsthoefel AM, Thompson EA. Glucocorticoid regulation of transcription of the c-myc cellular protooncogene in P1798 cells. Mol Endocrinol 1987; 1: 899-907.
140. Tosa N, Murakami M, Jia WY, Yokoyama M, Masunaga T, Iwabuchi C, Inobe M, Iwabuchi K, Miyazaki T, Onoe K, Iwata M, Uede T. Critical function of T cell death-associated gene 8 in glucocorticoid-induced thymocyte apoptosis. lnt Immunol 2003; 15: 741-9.
141. Tonko M, Ausserlechner MJ, Bernhard D, Helmberg A, Kofler R. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis. FASEB J 2001; 15: 693-9.
142. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003; 278: 23861-7.
143. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM, Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419: 634-7.
144. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Konigen F, Adams JM, Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-8.
145. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-40.
146. Jia L, Macey MG, Yin Y, Newland AC, Kelsey SM. Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood 1999; 93: 2353-9.
147. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bc1-X(L) during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-72.
148. van den Brandt J, Wang D, Reichardt HM. Resistance of single-positive thymocytes to glucocorticoid-induced apoptosis is mediated by CD28 signaling. Mol Endocrinol 2004; 18: 687-95.
149. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al. Massive cell death of immature hematopoietic cells and neurons in Bc1-x-deficient mice. Science 1995; 267: 1506-10.
150. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3: 932-9.
151. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels H.A., Ulrich E, Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, Eng VM, Adelman DM, Simon MC, Ma A, Golden JA, Evan G, Korsmeyer SJ, MacGregor GR, Thompson CB. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-99.
152. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-6.
153. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.
154. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-91.
155. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM, Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-8.
156. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996; 15: 3835-44.
157. Tonomura N, McLaughlin K, Grimm L, Goldsby RA, Osborne BA. Glucocorticoid-induced apoptosis of thymocytes: Requirement of proteasome-dependent mitochondrial activity. J Immunol 2003; 170: 2469-78.
158. He H, Qi XM, Grossmann J, Distelhorst CW. c-Fos degradation by the proteasome. An early, Bc1-2-regulated step in apoptosis. J Biol Chem 1998; 273: 25015-9.
159. Gil-Gomez G, Berns A, Brady HJ. A link between cell cycle and cell death: Bax and Bc1-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J 1998; 17: 7209-18.
160. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288: 874-7.
161. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002; 3: 1129-34.
162. Cifone MG, Migliorati G, Parroni R, Marchetti C, Millimaggi D, Santoni A, Riccardi C. Dexamethasone-induced thymocyte apoptosis: Apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. Blood 1999; 93: 2282-96.
163. Jayaraman T, Marks AR. T cells deficient in inositol 1,4,5-trisphosphate receptor are resistant to apoptosis. Mol Cell Biol 1997; 17: 3005-12.
164. + efflux in the activation of apoptosis. J Biol Chem 1997; 272: 32436-42.
165. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 9: 6-19.
166. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. Substrate specificities of caspase family proteases. J Biol Chem 1997; 272: 9677-82.
167. Mann CL, Hughes FM Jr, Cidlowski JA. Delineation of the signaling pathways involved in glucocorticoid-induced and spontaneous apoptosis of rat thymocytes. Endocrinology 2000; 141: 528-38.
168. Hughes FM Jr, Cidlowski JA. Glucocorticoid-induced thymocyte apoptosis: Protease-dependent activation of cell shrinkage and DNA degradation. J Steroid Biochem Mol Biol 1998; 65: 207-17.
169. Marchetti MC, Di Marco B, Cifone G, Migliorati G, Riccardi C. Dexamethasone-induced apoptosis of thymocytes: Role of glucocorticoid receptor-associated Src kinase and caspase-8 activation. Blood 2003; 101: 585-93.
170. Li P, Alien H, Banerjee S, Seshadri T. Characterization of mice deficient in interleukin-1 beta converting enzyme. J Cell Biochem 1997; 64: 27-32.
171. Salmena L, Lemmers B, Hakem A, Matysiak-Zablocki E, Murakami K, Au PY, Berry DM, Tamblyn L, Shehabeldin A, Migon E, Wakeham A, Bouchard D, Yeh WC, McGlade JC, Ohashi PS, Hakem R. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 2003; 17: 883-95.
172. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, Kuida K, Strasser A, Huang DC, Kumar S. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ 2002; 9: 832-41.
173. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, Su MS, Rakic P, Flavell RA. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998; 94: 325-37.
174. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, Hakem R, Penninger JM, Mak TW. Apaf 1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998; 94: 739-50.
175. Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, Rakic P, Flavell RA. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996; 384: 368-72.
176. Screpanti I, Morrone S, Meco D, Santoni A, Gulino A, Paolini R, Crisanti A, Mathieson BJ, Frati L. Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J Immunol 1989; 142: 3378-83.
177. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 109: 295-9.
178. Tacke M, Clark GJ, Dallman MJ, Hünig T. Cellular distribution and costimulatory function of rat CD28. Regulated expression during thymocyte maturation and induction of cyclosporin A sensitivity of costimulated T cell responses by phorbol ester. J Immunol 1995; 154: 5121-7.
179. Wagner DH Jr, Hagman J, Linsley PS, Hodsdon W, Freed JH, Newell MK. Rescue of thymocytes from glucocorticoid-induced cell death mediated by CD28/CTLA-4 costimulatory interactions with B7-l/B7-2. J Exp Med 1996; 184: 1631-8.
180. Reiser H, Schneeberger EE. The costimulatory molecule B7 is expressed in the medullary region of the murine thymus. Immunology 1994; 81: 532-7.
181. Noel PJ, Alegre ML, Reiner SL, Thompson CB. Impaired negative selection in CD28-deficient mice. Cell Immunol 1998; 187: 131-8.
182. Vacchio MS, Ashwell JD. Glucocorticoids and thymocyte development. Semin Immunol 2000; 12: 475-85.
183. Bevan MJ. In thymic selection, peptide diversity gives and takes away. Immunity 1997; 7: 175-8.
184. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol 2002; 2: 309-22.
185. King LB, Vacchio MS, Dixon K, Hunziker R, Margulies DH, Ashwell JD. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. Immunity 1995; 3: 647-56.
186. Lu FW, Yasutomo K, Goodman GB, McHeyzer-Williams LJ, McHeyzer-Williams MG, Germain RN, Ashwell JD. Thymocyte resistance to glucocorticoids leads to antigen-specific unresponsiveness due to "holes" in the T cell repertoire. Immunity 2000; 12: 183-92.
187. Tolosa E, King LB, Ashwell JD. Thymocyte glucocorticoid resistance alters positive selection and inhibits autoimmunity and lymphoproliferative disease in MRL-1pr/1pr mice. Immunity 1998; 8: 67-76.